Robert Griffin
Concepts (741)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 38 | 2024 | 1325 | 5.060 |
Why?
| Hyperthermia, Induced | 17 | 2019 | 120 | 3.530 |
Why?
| Mammary Neoplasms, Experimental | 12 | 2015 | 122 | 3.180 |
Why?
| Radiotherapy | 10 | 2021 | 127 | 2.910 |
Why?
| Air Pollutants | 13 | 2024 | 75 | 2.830 |
Why?
| Gold | 9 | 2023 | 128 | 2.530 |
Why?
| Bystander Effect | 5 | 2024 | 25 | 2.050 |
Why?
| Mice | 75 | 2024 | 5949 | 2.010 |
Why?
| Radiation-Sensitizing Agents | 11 | 2023 | 52 | 2.000 |
Why?
| Animals | 101 | 2024 | 13505 | 1.950 |
Why?
| Nanostructures | 5 | 2023 | 48 | 1.800 |
Why?
| Cell Line, Tumor | 39 | 2024 | 1470 | 1.670 |
Why?
| Exosomes | 7 | 2022 | 58 | 1.600 |
Why?
| Angiogenesis Inhibitors | 8 | 2017 | 183 | 1.540 |
Why?
| Phototherapy | 5 | 2022 | 42 | 1.530 |
Why?
| Radiation Tolerance | 9 | 2020 | 84 | 1.480 |
Why?
| Metal Nanoparticles | 4 | 2023 | 86 | 1.440 |
Why?
| Blood Vessels | 9 | 2020 | 71 | 1.430 |
Why?
| Nanoparticles | 6 | 2022 | 160 | 1.400 |
Why?
| Neoplasms, Experimental | 6 | 2020 | 114 | 1.390 |
Why?
| Lung Neoplasms | 10 | 2024 | 636 | 1.370 |
Why?
| Galectin 1 | 4 | 2017 | 21 | 1.350 |
Why?
| Environmental Monitoring | 8 | 2024 | 74 | 1.330 |
Why?
| Aerosols | 10 | 2023 | 75 | 1.330 |
Why?
| Oxygen | 12 | 2020 | 336 | 1.300 |
Why?
| Polyethylene Glycols | 4 | 2022 | 90 | 1.270 |
Why?
| Air Pollution | 3 | 2024 | 49 | 1.230 |
Why?
| Particulate Matter | 5 | 2024 | 63 | 1.210 |
Why?
| Carcinoma, Squamous Cell | 6 | 2019 | 332 | 1.190 |
Why?
| Combined Modality Therapy | 17 | 2022 | 639 | 1.090 |
Why?
| Humans | 113 | 2024 | 52483 | 1.080 |
Why?
| Endothelial Cells | 7 | 2021 | 262 | 1.070 |
Why?
| Tumor Necrosis Factor-alpha | 8 | 2019 | 399 | 1.010 |
Why?
| Sulfates | 2 | 2023 | 25 | 0.980 |
Why?
| Proteins | 7 | 2023 | 348 | 0.980 |
Why?
| Radiosurgery | 8 | 2024 | 131 | 0.980 |
Why?
| Neovascularization, Pathologic | 9 | 2021 | 153 | 0.980 |
Why?
| Fibrosarcoma | 7 | 2019 | 16 | 0.970 |
Why?
| Apoptosis | 10 | 2024 | 1119 | 0.960 |
Why?
| Antineoplastic Agents | 13 | 2024 | 1222 | 0.900 |
Why?
| Liposomes | 2 | 2022 | 54 | 0.890 |
Why?
| Oxygen Consumption | 4 | 2020 | 198 | 0.880 |
Why?
| Peptides | 10 | 2022 | 223 | 0.870 |
Why?
| Ozone | 6 | 2022 | 20 | 0.860 |
Why?
| Benzeneacetamides | 2 | 2024 | 12 | 0.840 |
Why?
| Glutaminase | 2 | 2024 | 18 | 0.840 |
Why?
| Diamond | 1 | 2023 | 1 | 0.840 |
Why?
| Microwaves | 1 | 2023 | 11 | 0.830 |
Why?
| Cell Communication | 3 | 2021 | 71 | 0.830 |
Why?
| Fluorescent Dyes | 5 | 2022 | 105 | 0.830 |
Why?
| Mice, Inbred BALB C | 8 | 2020 | 312 | 0.830 |
Why?
| Radiotherapy, Intensity-Modulated | 5 | 2022 | 184 | 0.780 |
Why?
| Pyrimidines | 10 | 2024 | 199 | 0.780 |
Why?
| Indocyanine Green | 2 | 2013 | 33 | 0.780 |
Why?
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 170 | 0.760 |
Why?
| Neoplastic Cells, Circulating | 3 | 2017 | 74 | 0.750 |
Why?
| Protein Kinase Inhibitors | 6 | 2024 | 227 | 0.720 |
Why?
| Thiadiazoles | 3 | 2024 | 18 | 0.700 |
Why?
| Cell Survival | 16 | 2024 | 612 | 0.700 |
Why?
| Flow Cytometry | 5 | 2017 | 478 | 0.700 |
Why?
| Conservation of Natural Resources | 6 | 2025 | 43 | 0.680 |
Why?
| Models, Theoretical | 9 | 2017 | 185 | 0.680 |
Why?
| Antioxidants | 2 | 2020 | 256 | 0.660 |
Why?
| Radiotherapy Dosage | 7 | 2022 | 255 | 0.660 |
Why?
| Radiation-Protective Agents | 1 | 2020 | 72 | 0.650 |
Why?
| Radiotherapy Planning, Computer-Assisted | 7 | 2023 | 262 | 0.650 |
Why?
| Radiation Dosage | 2 | 2020 | 163 | 0.640 |
Why?
| Immunotherapy | 2 | 2021 | 244 | 0.640 |
Why?
| Head and Neck Neoplasms | 3 | 2019 | 288 | 0.610 |
Why?
| Ecosystem | 5 | 2017 | 96 | 0.590 |
Why?
| Aniline Compounds | 5 | 2024 | 46 | 0.590 |
Why?
| Epigenesis, Genetic | 2 | 2019 | 406 | 0.590 |
Why?
| Information Dissemination | 2 | 2016 | 84 | 0.590 |
Why?
| Drug Delivery Systems | 2 | 2022 | 154 | 0.590 |
Why?
| Arsenicals | 3 | 2007 | 15 | 0.580 |
Why?
| Oxides | 3 | 2007 | 21 | 0.580 |
Why?
| Cell Proliferation | 12 | 2024 | 1023 | 0.570 |
Why?
| Molecular Imaging | 2 | 2015 | 55 | 0.570 |
Why?
| Uncertainty | 2 | 2022 | 44 | 0.570 |
Why?
| Female | 38 | 2022 | 28171 | 0.570 |
Why?
| Xenograft Model Antitumor Assays | 13 | 2021 | 220 | 0.550 |
Why?
| Disease Models, Animal | 11 | 2020 | 1478 | 0.550 |
Why?
| Gamma Rays | 2 | 2020 | 49 | 0.550 |
Why?
| Oxidation-Reduction | 5 | 2023 | 326 | 0.540 |
Why?
| Bone and Bones | 2 | 2012 | 494 | 0.540 |
Why?
| Radiotherapy, Conformal | 2 | 2019 | 53 | 0.540 |
Why?
| Pneumonia, Viral | 1 | 2020 | 178 | 0.540 |
Why?
| Coronavirus Infections | 1 | 2020 | 188 | 0.530 |
Why?
| Science | 1 | 2016 | 20 | 0.530 |
Why?
| Wind | 3 | 2025 | 7 | 0.530 |
Why?
| Molecular Targeted Therapy | 3 | 2018 | 133 | 0.520 |
Why?
| Mice, Nude | 12 | 2019 | 265 | 0.520 |
Why?
| Radiobiology | 5 | 2023 | 21 | 0.520 |
Why?
| Enzyme Inhibitors | 7 | 2024 | 372 | 0.500 |
Why?
| Mouth Neoplasms | 4 | 2015 | 22 | 0.500 |
Why?
| Texas | 7 | 2024 | 143 | 0.480 |
Why?
| Pandemics | 1 | 2020 | 585 | 0.480 |
Why?
| Cell Hypoxia | 6 | 2015 | 83 | 0.470 |
Why?
| Carcinoma | 2 | 2013 | 138 | 0.450 |
Why?
| Exons | 3 | 2024 | 102 | 0.450 |
Why?
| Laser Therapy | 2 | 2013 | 82 | 0.450 |
Why?
| Solanum tuberosum | 1 | 2014 | 5 | 0.450 |
Why?
| Sanitation | 1 | 2014 | 18 | 0.440 |
Why?
| Radiation Oncology | 3 | 2024 | 25 | 0.440 |
Why?
| Bone Marrow Neoplasms | 1 | 2013 | 13 | 0.430 |
Why?
| Coloring Agents | 2 | 2013 | 69 | 0.430 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 857 | 0.420 |
Why?
| Chemokines | 1 | 2013 | 79 | 0.420 |
Why?
| Spectrum Analysis, Raman | 3 | 2019 | 56 | 0.420 |
Why?
| Plasmodium falciparum | 2 | 2024 | 26 | 0.420 |
Why?
| Malaria, Falciparum | 2 | 2024 | 23 | 0.410 |
Why?
| Infrared Rays | 2 | 2019 | 26 | 0.410 |
Why?
| Tumor Cells, Cultured | 8 | 2019 | 460 | 0.410 |
Why?
| Tumor Microenvironment | 7 | 2022 | 256 | 0.410 |
Why?
| Signal Transduction | 8 | 2021 | 1671 | 0.400 |
Why?
| Indoles | 4 | 2024 | 278 | 0.400 |
Why?
| Cell Death | 7 | 2019 | 177 | 0.390 |
Why?
| Adult Stem Cells | 1 | 2012 | 10 | 0.390 |
Why?
| Antibodies, Monoclonal | 3 | 2020 | 481 | 0.380 |
Why?
| Lignin | 1 | 2011 | 2 | 0.380 |
Why?
| DNA Damage | 5 | 2019 | 305 | 0.380 |
Why?
| Environmental Pollution | 1 | 2011 | 14 | 0.370 |
Why?
| Time Factors | 12 | 2017 | 2968 | 0.370 |
Why?
| Bone Neoplasms | 2 | 2011 | 184 | 0.370 |
Why?
| Mice, Inbred C3H | 9 | 2015 | 83 | 0.360 |
Why?
| Dose-Response Relationship, Radiation | 10 | 2020 | 184 | 0.360 |
Why?
| Models, Biological | 6 | 2018 | 735 | 0.360 |
Why?
| Photochemical Processes | 1 | 2010 | 9 | 0.350 |
Why?
| Saliva | 3 | 2007 | 56 | 0.350 |
Why?
| Photons | 2 | 2020 | 20 | 0.350 |
Why?
| Cytokines | 1 | 2013 | 623 | 0.340 |
Why?
| Phenols | 1 | 2011 | 92 | 0.340 |
Why?
| Breast Neoplasms | 6 | 2017 | 1212 | 0.330 |
Why?
| Cell Line | 6 | 2021 | 1030 | 0.330 |
Why?
| Melanoma, Experimental | 2 | 2021 | 40 | 0.330 |
Why?
| Magnetic Resonance Spectroscopy | 2 | 2023 | 253 | 0.330 |
Why?
| Rats | 11 | 2022 | 3220 | 0.330 |
Why?
| Methionine | 3 | 2020 | 136 | 0.330 |
Why?
| Mutagenesis, Insertional | 3 | 2024 | 24 | 0.330 |
Why?
| Oceans and Seas | 3 | 2025 | 30 | 0.320 |
Why?
| Radiation Injuries | 3 | 2020 | 110 | 0.320 |
Why?
| Volatile Organic Compounds | 2 | 2022 | 8 | 0.310 |
Why?
| Hydroxyl Radical | 2 | 2010 | 6 | 0.310 |
Why?
| Glutamine | 3 | 2024 | 176 | 0.310 |
Why?
| Atmosphere | 4 | 2019 | 11 | 0.310 |
Why?
| Receptor, erbB-2 | 5 | 2016 | 80 | 0.300 |
Why?
| Reactive Oxygen Species | 3 | 2024 | 421 | 0.300 |
Why?
| Radiation | 2 | 2020 | 14 | 0.300 |
Why?
| Drug Carriers | 2 | 2013 | 73 | 0.300 |
Why?
| Weightlessness Simulation | 2 | 2020 | 22 | 0.290 |
Why?
| Precancerous Conditions | 2 | 2010 | 85 | 0.290 |
Why?
| Male | 22 | 2024 | 26761 | 0.290 |
Why?
| History, 20th Century | 3 | 2020 | 96 | 0.290 |
Why?
| Caspase Inhibitors | 1 | 2008 | 16 | 0.290 |
Why?
| Cell Membrane Permeability | 1 | 2008 | 25 | 0.290 |
Why?
| Mice, SCID | 3 | 2024 | 182 | 0.290 |
Why?
| Cities | 3 | 2024 | 30 | 0.280 |
Why?
| Clinical Laboratory Techniques | 1 | 2008 | 28 | 0.280 |
Why?
| China | 3 | 2023 | 134 | 0.280 |
Why?
| Forecasting | 4 | 2020 | 154 | 0.280 |
Why?
| Carbon Radioisotopes | 2 | 2024 | 54 | 0.280 |
Why?
| Nanomedicine | 2 | 2024 | 20 | 0.280 |
Why?
| Freezing | 2 | 2004 | 16 | 0.280 |
Why?
| Caspases | 1 | 2007 | 104 | 0.280 |
Why?
| Adenocarcinoma | 1 | 2011 | 405 | 0.270 |
Why?
| Vascular Neoplasms | 1 | 2007 | 17 | 0.270 |
Why?
| Fisheries | 2 | 2025 | 11 | 0.270 |
Why?
| Nanotubes, Carbon | 2 | 2017 | 69 | 0.260 |
Why?
| Radiotherapy, Image-Guided | 2 | 2016 | 25 | 0.260 |
Why?
| Glutathione | 2 | 2019 | 305 | 0.250 |
Why?
| Risk Assessment | 3 | 2017 | 1327 | 0.250 |
Why?
| Microscopy, Fluorescence | 3 | 2018 | 160 | 0.250 |
Why?
| Melanoma | 2 | 2020 | 288 | 0.250 |
Why?
| Cryotherapy | 2 | 2011 | 12 | 0.250 |
Why?
| Radiometry | 3 | 2016 | 127 | 0.240 |
Why?
| Energy-Generating Resources | 1 | 2025 | 1 | 0.240 |
Why?
| Organs at Risk | 3 | 2022 | 75 | 0.240 |
Why?
| Renewable Energy | 1 | 2025 | 2 | 0.240 |
Why?
| Hindlimb | 2 | 2004 | 32 | 0.240 |
Why?
| Tyrosine-tRNA Ligase | 1 | 2024 | 1 | 0.240 |
Why?
| Administration, Oral | 6 | 2024 | 451 | 0.230 |
Why?
| Hydrogen-Ion Concentration | 5 | 2005 | 178 | 0.230 |
Why?
| Ovarian Neoplasms | 2 | 2008 | 459 | 0.230 |
Why?
| Doxorubicin | 2 | 2024 | 241 | 0.230 |
Why?
| Antimalarials | 1 | 2024 | 32 | 0.230 |
Why?
| Cell Culture Techniques | 2 | 2019 | 102 | 0.230 |
Why?
| Disease Progression | 4 | 2019 | 871 | 0.220 |
Why?
| Endocytosis | 1 | 2024 | 52 | 0.220 |
Why?
| Oxidants, Photochemical | 1 | 2004 | 3 | 0.220 |
Why?
| Smog | 1 | 2004 | 5 | 0.220 |
Why?
| Floods | 2 | 2021 | 3 | 0.220 |
Why?
| Porphyrins | 1 | 2023 | 10 | 0.220 |
Why?
| Oxidants | 1 | 2004 | 51 | 0.220 |
Why?
| Nitroimidazoles | 2 | 2015 | 16 | 0.220 |
Why?
| Clinical Trials as Topic | 3 | 2023 | 467 | 0.220 |
Why?
| Vascular Endothelial Growth Factor A | 5 | 2017 | 182 | 0.220 |
Why?
| Proteomics | 4 | 2021 | 329 | 0.220 |
Why?
| Photochemotherapy | 1 | 2023 | 34 | 0.210 |
Why?
| Sulfur Oxides | 1 | 2023 | 1 | 0.210 |
Why?
| Gulf of Mexico | 1 | 2023 | 7 | 0.210 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2021 | 117 | 0.210 |
Why?
| Receptor Protein-Tyrosine Kinases | 2 | 2008 | 52 | 0.210 |
Why?
| Carcinoma, Hepatocellular | 2 | 2023 | 202 | 0.210 |
Why?
| Partial Pressure | 3 | 2011 | 14 | 0.210 |
Why?
| Halogens | 1 | 2022 | 3 | 0.200 |
Why?
| Phosphatidylethanolamines | 1 | 2022 | 11 | 0.200 |
Why?
| Organic Anion Transporters | 1 | 2022 | 1 | 0.200 |
Why?
| Lipid Bilayers | 1 | 2022 | 12 | 0.200 |
Why?
| Tumor Burden | 3 | 2010 | 136 | 0.200 |
Why?
| Environmental Exposure | 2 | 2022 | 216 | 0.200 |
Why?
| Bile | 1 | 2022 | 23 | 0.200 |
Why?
| Chloral Hydrate | 1 | 2022 | 18 | 0.200 |
Why?
| Parasites | 1 | 2002 | 3 | 0.200 |
Why?
| Water Pollution | 1 | 2002 | 9 | 0.200 |
Why?
| Tissue Distribution | 1 | 2022 | 171 | 0.200 |
Why?
| Receptors, Growth Factor | 1 | 2002 | 7 | 0.190 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2002 | 8 | 0.190 |
Why?
| Protein Binding | 5 | 2020 | 667 | 0.190 |
Why?
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 5 | 0.190 |
Why?
| Glucocorticoids | 2 | 2022 | 235 | 0.190 |
Why?
| X-Rays | 3 | 2016 | 55 | 0.190 |
Why?
| Biological Transport | 2 | 2021 | 160 | 0.190 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 3 | 2007 | 13 | 0.190 |
Why?
| Low Back Pain | 1 | 2022 | 31 | 0.190 |
Why?
| Naphthoquinones | 3 | 2007 | 10 | 0.190 |
Why?
| Protons | 1 | 2022 | 70 | 0.190 |
Why?
| Liver Neoplasms | 2 | 2023 | 333 | 0.190 |
Why?
| Bone Resorption | 2 | 2022 | 302 | 0.190 |
Why?
| Cholesterol | 1 | 2022 | 153 | 0.190 |
Why?
| Postmenopause | 1 | 2022 | 82 | 0.190 |
Why?
| Pyrroles | 1 | 2002 | 71 | 0.190 |
Why?
| Boron Compounds | 1 | 2021 | 19 | 0.190 |
Why?
| Nucleotides, Cyclic | 1 | 2021 | 5 | 0.180 |
Why?
| Neoplasm Proteins | 3 | 2017 | 334 | 0.180 |
Why?
| High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 14 | 0.180 |
Why?
| Spheroids, Cellular | 3 | 2019 | 27 | 0.180 |
Why?
| Optical Imaging | 2 | 2020 | 26 | 0.180 |
Why?
| Endosomes | 1 | 2021 | 36 | 0.180 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2021 | 19 | 0.180 |
Why?
| Bone Remodeling | 1 | 2022 | 155 | 0.180 |
Why?
| Radiation, Ionizing | 4 | 2018 | 101 | 0.180 |
Why?
| Cells, Cultured | 4 | 2020 | 1567 | 0.180 |
Why?
| Proprioception | 1 | 2020 | 7 | 0.170 |
Why?
| Proteasome Inhibitors | 1 | 2021 | 104 | 0.170 |
Why?
| Ankle | 1 | 2020 | 14 | 0.170 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 59 | 0.170 |
Why?
| Chronic Pain | 1 | 2023 | 177 | 0.170 |
Why?
| Proton Therapy | 1 | 2020 | 12 | 0.170 |
Why?
| Spectrum Analysis | 1 | 2020 | 69 | 0.170 |
Why?
| Cell Transformation, Neoplastic | 3 | 2018 | 184 | 0.170 |
Why?
| Thymus Gland | 1 | 2020 | 41 | 0.170 |
Why?
| History, 21st Century | 1 | 2020 | 59 | 0.170 |
Why?
| Neural Stem Cells | 1 | 2020 | 26 | 0.170 |
Why?
| Adenosine Triphosphate | 1 | 2021 | 205 | 0.170 |
Why?
| Cell Differentiation | 2 | 2020 | 665 | 0.170 |
Why?
| Heavy Ion Radiotherapy | 1 | 2019 | 2 | 0.160 |
Why?
| Receptor, TIE-2 | 2 | 2017 | 16 | 0.160 |
Why?
| Carcinoma, Lewis Lung | 1 | 2019 | 9 | 0.160 |
Why?
| Spleen | 1 | 2020 | 172 | 0.160 |
Why?
| Public Health | 1 | 2002 | 223 | 0.160 |
Why?
| Calixarenes | 2 | 2017 | 9 | 0.160 |
Why?
| Whole-Body Irradiation | 1 | 2020 | 127 | 0.160 |
Why?
| Osteogenesis | 1 | 2022 | 366 | 0.160 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 134 | 0.160 |
Why?
| Autoantibodies | 1 | 2020 | 121 | 0.160 |
Why?
| Societies, Medical | 1 | 2020 | 200 | 0.160 |
Why?
| Cone-Beam Computed Tomography | 2 | 2016 | 34 | 0.160 |
Why?
| Interleukin-6 | 2 | 2020 | 278 | 0.160 |
Why?
| Cyclonic Storms | 2 | 2017 | 8 | 0.160 |
Why?
| Preservation, Biological | 1 | 2018 | 9 | 0.150 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 78 | 0.150 |
Why?
| Drug Evaluation, Preclinical | 3 | 2015 | 146 | 0.150 |
Why?
| Membrane Proteins | 1 | 2021 | 335 | 0.150 |
Why?
| Astrocytes | 1 | 2020 | 137 | 0.150 |
Why?
| Ephrin-B2 | 1 | 2018 | 5 | 0.150 |
Why?
| Paracrine Communication | 1 | 2018 | 12 | 0.150 |
Why?
| Cystic Fibrosis | 1 | 2021 | 154 | 0.150 |
Why?
| Methionine Adenosyltransferase | 1 | 2018 | 19 | 0.150 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 132 | 0.150 |
Why?
| Myocytes, Cardiac | 1 | 2019 | 129 | 0.150 |
Why?
| Environmental Pollutants | 1 | 2020 | 106 | 0.150 |
Why?
| Microinjections | 1 | 2018 | 35 | 0.150 |
Why?
| Biological Assay | 1 | 2018 | 47 | 0.150 |
Why?
| Receptors, Fc | 1 | 2018 | 10 | 0.150 |
Why?
| Treatment Outcome | 5 | 2020 | 5422 | 0.150 |
Why?
| Lipopolysaccharides | 1 | 2019 | 206 | 0.150 |
Why?
| Calibration | 1 | 2018 | 57 | 0.150 |
Why?
| Prostatic Neoplasms | 2 | 2013 | 398 | 0.150 |
Why?
| Galectins | 1 | 2018 | 7 | 0.150 |
Why?
| Histocompatibility Antigens Class I | 1 | 2018 | 48 | 0.150 |
Why?
| Ubiquitin-Activating Enzymes | 1 | 2018 | 4 | 0.150 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 105 | 0.150 |
Why?
| Nucleosides | 1 | 2018 | 5 | 0.150 |
Why?
| Indazoles | 1 | 2018 | 47 | 0.140 |
Why?
| Gastrointestinal Tract | 1 | 2019 | 108 | 0.140 |
Why?
| Erythrocyte Membrane | 1 | 2017 | 14 | 0.140 |
Why?
| California | 4 | 2010 | 90 | 0.140 |
Why?
| Particle Size | 2 | 2024 | 82 | 0.140 |
Why?
| Structure-Activity Relationship | 7 | 2021 | 404 | 0.140 |
Why?
| Scavenger Receptors, Class E | 1 | 2019 | 204 | 0.140 |
Why?
| Histocompatibility Antigens Class II | 1 | 2017 | 36 | 0.140 |
Why?
| Small Molecule Libraries | 1 | 2018 | 67 | 0.140 |
Why?
| Models, Molecular | 4 | 2021 | 348 | 0.140 |
Why?
| MicroRNAs | 1 | 2021 | 387 | 0.140 |
Why?
| Natural Science Disciplines | 1 | 2017 | 2 | 0.140 |
Why?
| Epitope Mapping | 1 | 2017 | 7 | 0.140 |
Why?
| Vehicle Emissions | 1 | 2017 | 10 | 0.140 |
Why?
| Receptors, Interleukin-6 | 1 | 2017 | 23 | 0.140 |
Why?
| United States | 5 | 2025 | 5192 | 0.140 |
Why?
| Muscle, Skeletal | 2 | 2020 | 804 | 0.130 |
Why?
| Silver | 1 | 2017 | 52 | 0.130 |
Why?
| Pyridazines | 2 | 2008 | 10 | 0.130 |
Why?
| Myocardial Infarction | 1 | 2021 | 412 | 0.130 |
Why?
| Bacteria | 1 | 2018 | 228 | 0.130 |
Why?
| Ammonia | 1 | 2017 | 86 | 0.130 |
Why?
| Sulfonamides | 1 | 2018 | 133 | 0.130 |
Why?
| Random Allocation | 2 | 2015 | 285 | 0.130 |
Why?
| Biomass | 1 | 2016 | 21 | 0.130 |
Why?
| Epithelial Cells | 1 | 2018 | 215 | 0.130 |
Why?
| Social Environment | 1 | 2017 | 81 | 0.130 |
Why?
| Mice, Inbred Strains | 3 | 2013 | 163 | 0.130 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1031 | 0.130 |
Why?
| Dendritic Cells | 1 | 2017 | 136 | 0.130 |
Why?
| Antibodies | 1 | 2017 | 159 | 0.130 |
Why?
| Linear Models | 2 | 2016 | 287 | 0.130 |
Why?
| Radiation Protection | 1 | 2016 | 47 | 0.130 |
Why?
| Extraterrestrial Environment | 1 | 2016 | 7 | 0.130 |
Why?
| Neoplasm Transplantation | 2 | 2007 | 87 | 0.120 |
Why?
| Chemistry, Organic | 2 | 2019 | 2 | 0.120 |
Why?
| Organ Specificity | 1 | 2016 | 115 | 0.120 |
Why?
| Extracellular Fluid | 1 | 2015 | 14 | 0.120 |
Why?
| Tomography, Spiral Computed | 1 | 2016 | 56 | 0.120 |
Why?
| Microbubbles | 1 | 2015 | 25 | 0.120 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2016 | 90 | 0.120 |
Why?
| Organ Sparing Treatments | 1 | 2016 | 57 | 0.120 |
Why?
| Multiple Myeloma | 1 | 2010 | 3049 | 0.120 |
Why?
| Sulfuric Acids | 1 | 2015 | 8 | 0.120 |
Why?
| Cell Count | 1 | 2015 | 149 | 0.120 |
Why?
| Stromal Cells | 1 | 2015 | 79 | 0.120 |
Why?
| Pressure | 1 | 2015 | 104 | 0.120 |
Why?
| Rabbits | 3 | 2010 | 375 | 0.120 |
Why?
| Necrosis | 3 | 2013 | 176 | 0.120 |
Why?
| Biomedical Research | 1 | 2018 | 256 | 0.120 |
Why?
| Tandem Mass Spectrometry | 3 | 2017 | 251 | 0.110 |
Why?
| Imaging, Three-Dimensional | 1 | 2015 | 154 | 0.110 |
Why?
| Carbon Dioxide | 2 | 2005 | 97 | 0.110 |
Why?
| Cisplatin | 2 | 2024 | 285 | 0.110 |
Why?
| Image Processing, Computer-Assisted | 1 | 2016 | 253 | 0.110 |
Why?
| Mexico | 1 | 2014 | 37 | 0.110 |
Why?
| Brain | 2 | 2020 | 1323 | 0.110 |
Why?
| Contrast Media | 1 | 2015 | 193 | 0.110 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2017 | 505 | 0.110 |
Why?
| Hot Temperature | 3 | 2013 | 214 | 0.110 |
Why?
| HEK293 Cells | 3 | 2020 | 229 | 0.110 |
Why?
| Animals, Inbred Strains | 1 | 2013 | 5 | 0.110 |
Why?
| Ultrasonography | 1 | 2015 | 430 | 0.110 |
Why?
| Nanoconjugates | 1 | 2013 | 1 | 0.110 |
Why?
| DNA Methylation | 1 | 2018 | 592 | 0.100 |
Why?
| Ions | 2 | 2024 | 32 | 0.100 |
Why?
| Food, Genetically Modified | 1 | 2013 | 1 | 0.100 |
Why?
| Stress, Psychological | 1 | 2015 | 273 | 0.100 |
Why?
| Food Labeling | 1 | 2013 | 5 | 0.100 |
Why?
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2013 | 4 | 0.100 |
Why?
| Antigen-Presenting Cells | 1 | 2013 | 23 | 0.100 |
Why?
| Societies, Scientific | 1 | 2013 | 14 | 0.100 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 185 | 0.100 |
Why?
| Nanospheres | 1 | 2013 | 8 | 0.100 |
Why?
| Nanotechnology | 1 | 2013 | 41 | 0.100 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2013 | 41 | 0.100 |
Why?
| Nutrition Policy | 1 | 2013 | 39 | 0.100 |
Why?
| Gene Expression Profiling | 2 | 2017 | 1105 | 0.100 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 582 | 0.100 |
Why?
| Mice, Inbred C57BL | 4 | 2020 | 1884 | 0.100 |
Why?
| Blotting, Western | 1 | 2013 | 590 | 0.100 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 405 | 0.100 |
Why?
| Film Dosimetry | 1 | 2012 | 15 | 0.100 |
Why?
| Glucose | 2 | 2011 | 355 | 0.100 |
Why?
| Surface Plasmon Resonance | 3 | 2017 | 23 | 0.100 |
Why?
| Middle Aged | 6 | 2024 | 13028 | 0.090 |
Why?
| RNA, Messenger | 2 | 2013 | 1132 | 0.090 |
Why?
| Gold Colloid | 2 | 2011 | 2 | 0.090 |
Why?
| North Carolina | 2 | 2022 | 56 | 0.090 |
Why?
| Acids | 1 | 2011 | 10 | 0.090 |
Why?
| Adult | 6 | 2024 | 14161 | 0.090 |
Why?
| Isomerism | 1 | 2011 | 24 | 0.090 |
Why?
| Gene Expression Regulation | 3 | 2021 | 990 | 0.090 |
Why?
| Copper | 1 | 2011 | 47 | 0.090 |
Why?
| Injections, Intravenous | 1 | 2011 | 138 | 0.090 |
Why?
| Aldehydes | 1 | 2011 | 81 | 0.090 |
Why?
| Immunohistochemistry | 2 | 2020 | 979 | 0.090 |
Why?
| Feces | 2 | 2024 | 153 | 0.090 |
Why?
| Acenaphthenes | 1 | 2010 | 1 | 0.090 |
Why?
| Nitrogen Oxides | 1 | 2010 | 3 | 0.090 |
Why?
| Drug Screening Assays, Antitumor | 3 | 2024 | 136 | 0.090 |
Why?
| T-Lymphocytes | 1 | 2013 | 340 | 0.090 |
Why?
| Positron-Emission Tomography | 1 | 2012 | 301 | 0.090 |
Why?
| Myosins | 1 | 2010 | 16 | 0.090 |
Why?
| Tomography, X-Ray Computed | 1 | 2016 | 1165 | 0.080 |
Why?
| Bone Transplantation | 1 | 2010 | 42 | 0.080 |
Why?
| Isoxazoles | 1 | 2009 | 15 | 0.080 |
Why?
| Nitrous Acid | 1 | 2009 | 1 | 0.080 |
Why?
| Free Radicals | 1 | 2009 | 28 | 0.080 |
Why?
| Abdomen | 1 | 2010 | 75 | 0.080 |
Why?
| Acetylcysteine | 1 | 2010 | 102 | 0.080 |
Why?
| Actins | 1 | 2010 | 115 | 0.080 |
Why?
| Microcirculation | 1 | 2010 | 64 | 0.080 |
Why?
| Protein Transport | 1 | 2010 | 180 | 0.080 |
Why?
| Aged | 5 | 2022 | 10121 | 0.080 |
Why?
| Naphthalenes | 1 | 2010 | 121 | 0.080 |
Why?
| Formaldehyde | 1 | 2009 | 51 | 0.080 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2009 | 56 | 0.080 |
Why?
| Coculture Techniques | 2 | 2020 | 144 | 0.080 |
Why?
| Chemotherapy, Adjuvant | 2 | 2016 | 124 | 0.080 |
Why?
| Glycolysis | 2 | 2021 | 73 | 0.080 |
Why?
| Young Adult | 3 | 2024 | 4329 | 0.080 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2009 | 39 | 0.080 |
Why?
| Prospective Studies | 3 | 2023 | 2481 | 0.080 |
Why?
| Glycogen Synthase Kinase 3 | 2 | 2008 | 21 | 0.080 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2008 | 10 | 0.080 |
Why?
| Growth Inhibitors | 2 | 2009 | 26 | 0.080 |
Why?
| Nerve Tissue Proteins | 2 | 2020 | 187 | 0.070 |
Why?
| Up-Regulation | 2 | 2007 | 454 | 0.070 |
Why?
| STAT3 Transcription Factor | 2 | 2020 | 85 | 0.070 |
Why?
| Evoked Potentials, Auditory, Brain Stem | 1 | 2008 | 24 | 0.070 |
Why?
| Methotrexate | 1 | 2009 | 77 | 0.070 |
Why?
| Drinking | 2 | 2020 | 43 | 0.070 |
Why?
| Insulin-Like Growth Factor I | 1 | 2009 | 139 | 0.070 |
Why?
| Alkynes | 1 | 2008 | 6 | 0.070 |
Why?
| Pyrrolidines | 1 | 2008 | 69 | 0.070 |
Why?
| Regional Blood Flow | 2 | 2005 | 109 | 0.070 |
Why?
| Cytotoxins | 1 | 2008 | 15 | 0.070 |
Why?
| Cryosurgery | 2 | 2011 | 36 | 0.070 |
Why?
| Chemical Fractionation | 1 | 2007 | 17 | 0.070 |
Why?
| Drug Synergism | 2 | 2005 | 150 | 0.070 |
Why?
| Fluorescence | 2 | 2018 | 39 | 0.070 |
Why?
| Toxicity Tests | 1 | 2008 | 57 | 0.070 |
Why?
| Cost-Benefit Analysis | 2 | 2021 | 267 | 0.070 |
Why?
| Enzyme Activation | 2 | 2005 | 270 | 0.070 |
Why?
| Skin | 2 | 2009 | 422 | 0.070 |
Why?
| Computer Simulation | 3 | 2016 | 290 | 0.070 |
Why?
| Oxidative Stress | 1 | 2012 | 807 | 0.070 |
Why?
| In Situ Nick-End Labeling | 2 | 2004 | 53 | 0.070 |
Why?
| Histones | 2 | 2020 | 314 | 0.070 |
Why?
| Sesquiterpenes | 1 | 2008 | 90 | 0.070 |
Why?
| Sulfides | 2 | 2018 | 29 | 0.070 |
Why?
| Neurons | 2 | 2020 | 418 | 0.070 |
Why?
| Hearing Loss, Sensorineural | 1 | 2008 | 79 | 0.070 |
Why?
| Angiopoietin-2 | 2 | 2017 | 15 | 0.070 |
Why?
| Angiopoietin-1 | 2 | 2017 | 16 | 0.070 |
Why?
| Concept Formation | 1 | 2006 | 12 | 0.070 |
Why?
| Fibroblast Growth Factor 2 | 2 | 2017 | 34 | 0.070 |
Why?
| Wetlands | 2 | 2017 | 5 | 0.070 |
Why?
| Interleukin-2 | 1 | 2006 | 69 | 0.070 |
Why?
| Coral Reefs | 2 | 2017 | 3 | 0.070 |
Why?
| Interleukin-8 | 1 | 2006 | 86 | 0.060 |
Why?
| Lasers | 2 | 2019 | 108 | 0.060 |
Why?
| Matrix Metalloproteinase 9 | 2 | 2017 | 87 | 0.060 |
Why?
| Sarcoma | 1 | 2007 | 72 | 0.060 |
Why?
| Mice, Inbred A | 2 | 2003 | 15 | 0.060 |
Why?
| Temperature | 3 | 2018 | 183 | 0.060 |
Why?
| Electrophoresis | 1 | 2005 | 16 | 0.060 |
Why?
| Feasibility Studies | 2 | 2022 | 406 | 0.060 |
Why?
| Sensitivity and Specificity | 3 | 2016 | 891 | 0.060 |
Why?
| Carbon | 1 | 2005 | 55 | 0.060 |
Why?
| Neoadjuvant Therapy | 2 | 2017 | 125 | 0.060 |
Why?
| Tumor Suppressor Proteins | 1 | 2006 | 130 | 0.060 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 236 | 0.060 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 64 | 0.060 |
Why?
| Electricity | 1 | 2025 | 7 | 0.060 |
Why?
| Alkanes | 1 | 2005 | 10 | 0.060 |
Why?
| Public Policy | 2 | 2015 | 38 | 0.060 |
Why?
| Neoplasm Staging | 2 | 2019 | 772 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 145 | 0.060 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 72 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2006 | 169 | 0.060 |
Why?
| Niacinamide | 1 | 2005 | 23 | 0.060 |
Why?
| Colorectal Neoplasms | 2 | 2006 | 294 | 0.060 |
Why?
| Transplantation, Heterologous | 2 | 2021 | 79 | 0.060 |
Why?
| Protozoan Proteins | 1 | 2024 | 32 | 0.060 |
Why?
| Organelles | 1 | 2024 | 15 | 0.060 |
Why?
| Rats, Inbred F344 | 1 | 2005 | 197 | 0.060 |
Why?
| Congresses as Topic | 1 | 2024 | 48 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 4 | 2009 | 1378 | 0.060 |
Why?
| Neoplasm Recurrence, Local | 1 | 2009 | 649 | 0.060 |
Why?
| Amines | 1 | 2004 | 38 | 0.060 |
Why?
| MCF-7 Cells | 1 | 2024 | 64 | 0.060 |
Why?
| Administration, Inhalation | 1 | 2005 | 120 | 0.060 |
Why?
| Kidney Diseases | 1 | 2007 | 220 | 0.060 |
Why?
| Lichen Planus, Oral | 1 | 2004 | 1 | 0.060 |
Why?
| Materials Testing | 1 | 2024 | 58 | 0.060 |
Why?
| Leukoplakia, Oral | 1 | 2004 | 6 | 0.060 |
Why?
| Drug Combinations | 2 | 2018 | 132 | 0.060 |
Why?
| Photochemistry | 1 | 2004 | 15 | 0.060 |
Why?
| Photoacoustic Techniques | 2 | 2016 | 71 | 0.060 |
Why?
| Buthionine Sulfoximine | 1 | 2024 | 13 | 0.060 |
Why?
| Hydrocarbons | 1 | 2004 | 14 | 0.060 |
Why?
| Binding Sites | 2 | 2021 | 377 | 0.060 |
Why?
| Biological Availability | 1 | 2024 | 108 | 0.050 |
Why?
| Cations | 1 | 2023 | 9 | 0.050 |
Why?
| Biocompatible Materials | 1 | 2024 | 67 | 0.050 |
Why?
| Carboplatin | 1 | 2024 | 57 | 0.050 |
Why?
| Monoterpenes | 1 | 2003 | 5 | 0.050 |
Why?
| Phosphorylation | 3 | 2017 | 528 | 0.050 |
Why?
| Statistics, Nonparametric | 1 | 2004 | 192 | 0.050 |
Why?
| Photosensitizing Agents | 1 | 2023 | 20 | 0.050 |
Why?
| Antibiotics, Antineoplastic | 1 | 2024 | 80 | 0.050 |
Why?
| Crystallography, X-Ray | 2 | 2018 | 156 | 0.050 |
Why?
| Multicenter Studies as Topic | 1 | 2023 | 105 | 0.050 |
Why?
| Mass Spectrometry | 2 | 2019 | 292 | 0.050 |
Why?
| Organic Chemicals | 1 | 2003 | 15 | 0.050 |
Why?
| Sphingomyelin Phosphodiesterase | 1 | 2003 | 11 | 0.050 |
Why?
| Hepatitis B virus | 1 | 2023 | 24 | 0.050 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 34 | 0.050 |
Why?
| DNA-Binding Proteins | 1 | 2006 | 422 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2005 | 246 | 0.050 |
Why?
| G2 Phase | 1 | 2003 | 13 | 0.050 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2016 | 30 | 0.050 |
Why?
| Quinazolines | 1 | 2003 | 34 | 0.050 |
Why?
| Mammary Neoplasms, Animal | 1 | 2003 | 35 | 0.050 |
Why?
| Prognosis | 2 | 2009 | 2099 | 0.050 |
Why?
| Anions | 1 | 2022 | 6 | 0.050 |
Why?
| Analysis of Variance | 1 | 2004 | 554 | 0.050 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2004 | 221 | 0.050 |
Why?
| Consensus | 1 | 2023 | 181 | 0.050 |
Why?
| Interferons | 1 | 2022 | 40 | 0.050 |
Why?
| Injections, Epidural | 1 | 2022 | 11 | 0.050 |
Why?
| Acetone | 1 | 2022 | 7 | 0.050 |
Why?
| Osteocalcin | 1 | 2022 | 45 | 0.050 |
Why?
| Rifampin | 1 | 2022 | 63 | 0.050 |
Why?
| Probability | 2 | 2016 | 172 | 0.050 |
Why?
| Polyphosphates | 1 | 2022 | 2 | 0.050 |
Why?
| Inositol | 1 | 2022 | 19 | 0.050 |
Why?
| Heating | 1 | 2022 | 5 | 0.050 |
Why?
| Pain Measurement | 1 | 2023 | 256 | 0.050 |
Why?
| Hepatocytes | 1 | 2023 | 190 | 0.050 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 23 | 0.050 |
Why?
| Propionates | 1 | 2002 | 24 | 0.050 |
Why?
| Hydrocortisone | 1 | 2022 | 111 | 0.050 |
Why?
| Reproducibility of Results | 2 | 2022 | 1229 | 0.050 |
Why?
| Demography | 1 | 2022 | 90 | 0.050 |
Why?
| Ferrets | 1 | 2021 | 7 | 0.050 |
Why?
| Pain Management | 1 | 2023 | 178 | 0.050 |
Why?
| Protein Isoforms | 1 | 2022 | 123 | 0.050 |
Why?
| Estuaries | 1 | 2021 | 2 | 0.050 |
Why?
| Bays | 1 | 2021 | 2 | 0.050 |
Why?
| Hydrodynamics | 1 | 2021 | 8 | 0.050 |
Why?
| Income | 1 | 2022 | 102 | 0.050 |
Why?
| San Francisco | 1 | 2021 | 13 | 0.050 |
Why?
| Models, Economic | 1 | 2021 | 16 | 0.050 |
Why?
| Drug Resistance, Neoplasm | 1 | 2024 | 326 | 0.050 |
Why?
| Catalytic Domain | 1 | 2021 | 60 | 0.050 |
Why?
| Mice, Inbred NOD | 1 | 2021 | 92 | 0.050 |
Why?
| Protein Structure, Tertiary | 2 | 2017 | 242 | 0.050 |
Why?
| Cricetinae | 1 | 2021 | 194 | 0.050 |
Why?
| Cell Division | 1 | 2002 | 291 | 0.050 |
Why?
| Aged, 80 and over | 2 | 2021 | 3392 | 0.050 |
Why?
| Half-Life | 1 | 2021 | 88 | 0.040 |
Why?
| Phosphates | 1 | 2021 | 49 | 0.040 |
Why?
| Analgesics, Opioid | 1 | 2007 | 590 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2021 | 73 | 0.040 |
Why?
| Micronucleus Tests | 1 | 2020 | 6 | 0.040 |
Why?
| Bayes Theorem | 1 | 2021 | 121 | 0.040 |
Why?
| Molecular Docking Simulation | 1 | 2021 | 88 | 0.040 |
Why?
| Cell Line, Transformed | 1 | 2021 | 74 | 0.040 |
Why?
| Software | 2 | 2016 | 280 | 0.040 |
Why?
| ROC Curve | 1 | 2021 | 253 | 0.040 |
Why?
| Skin Temperature | 1 | 2020 | 17 | 0.040 |
Why?
| Feedback, Physiological | 1 | 2020 | 12 | 0.040 |
Why?
| Catecholamines | 1 | 2020 | 44 | 0.040 |
Why?
| Limbic Encephalitis | 1 | 2020 | 2 | 0.040 |
Why?
| Elastin | 1 | 2020 | 23 | 0.040 |
Why?
| Monte Carlo Method | 1 | 2020 | 87 | 0.040 |
Why?
| Primary Cell Culture | 1 | 2020 | 62 | 0.040 |
Why?
| ADAM Proteins | 1 | 2020 | 20 | 0.040 |
Why?
| Epitopes | 1 | 2020 | 65 | 0.040 |
Why?
| Autoantigens | 1 | 2020 | 53 | 0.040 |
Why?
| Antiviral Agents | 1 | 2021 | 178 | 0.040 |
Why?
| HeLa Cells | 1 | 2020 | 265 | 0.040 |
Why?
| Bone Density | 1 | 2022 | 399 | 0.040 |
Why?
| Cytoprotection | 1 | 2019 | 33 | 0.040 |
Why?
| Facility Design and Construction | 1 | 2019 | 3 | 0.040 |
Why?
| Muscle Contraction | 1 | 2020 | 117 | 0.040 |
Why?
| Endothelium | 1 | 2019 | 37 | 0.040 |
Why?
| Energy Intake | 1 | 2020 | 174 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 61 | 0.040 |
Why?
| Glioma | 1 | 2020 | 78 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 57 | 0.040 |
Why?
| Pancreatic Neoplasms | 1 | 2002 | 216 | 0.040 |
Why?
| Stress, Physiological | 1 | 2020 | 183 | 0.040 |
Why?
| Diffusion Chambers, Culture | 1 | 2018 | 7 | 0.040 |
Why?
| Swine | 2 | 2011 | 428 | 0.040 |
Why?
| Skin Neoplasms | 1 | 2004 | 505 | 0.040 |
Why?
| Culture Media, Serum-Free | 1 | 2018 | 15 | 0.040 |
Why?
| Culture Media, Conditioned | 1 | 2018 | 47 | 0.040 |
Why?
| Laminin | 1 | 2018 | 19 | 0.040 |
Why?
| Hep G2 Cells | 1 | 2018 | 39 | 0.040 |
Why?
| Program Development | 1 | 2019 | 165 | 0.040 |
Why?
| Specimen Handling | 1 | 2018 | 56 | 0.040 |
Why?
| Flavin-Adenine Dinucleotide | 1 | 2018 | 4 | 0.040 |
Why?
| Dextrans | 1 | 2018 | 16 | 0.040 |
Why?
| Follow-Up Studies | 1 | 2004 | 2279 | 0.040 |
Why?
| Allosteric Site | 1 | 2018 | 2 | 0.040 |
Why?
| Calcium-Binding Proteins | 1 | 2018 | 56 | 0.040 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 36 | 0.040 |
Why?
| Surface Properties | 1 | 2018 | 62 | 0.040 |
Why?
| NAD | 1 | 2018 | 45 | 0.040 |
Why?
| Body Weight | 1 | 2020 | 523 | 0.040 |
Why?
| Hippocampus | 1 | 2020 | 201 | 0.040 |
Why?
| Proteoglycans | 1 | 2018 | 87 | 0.040 |
Why?
| Imides | 1 | 2018 | 1 | 0.040 |
Why?
| Mid-Atlantic Region | 1 | 2017 | 4 | 0.040 |
Why?
| New England | 1 | 2017 | 10 | 0.040 |
Why?
| Autophagy | 1 | 2019 | 193 | 0.040 |
Why?
| Carbohydrates | 1 | 2018 | 41 | 0.040 |
Why?
| Human Activities | 1 | 2017 | 7 | 0.040 |
Why?
| Macaca fascicularis | 1 | 2017 | 11 | 0.040 |
Why?
| Ubiquitin | 1 | 2018 | 47 | 0.040 |
Why?
| Caco-2 Cells | 1 | 2017 | 31 | 0.040 |
Why?
| Guidelines as Topic | 1 | 2018 | 111 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2018 | 90 | 0.040 |
Why?
| Ligands | 1 | 2018 | 206 | 0.040 |
Why?
| Cooperative Behavior | 1 | 2019 | 227 | 0.040 |
Why?
| Neoplasm Metastasis | 1 | 2018 | 243 | 0.040 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 202 | 0.030 |
Why?
| Nanotubes | 1 | 2017 | 27 | 0.030 |
Why?
| Phagocytosis | 1 | 2017 | 53 | 0.030 |
Why?
| Cell Movement | 1 | 2018 | 268 | 0.030 |
Why?
| Drug Interactions | 1 | 2017 | 206 | 0.030 |
Why?
| Collagen | 1 | 2018 | 211 | 0.030 |
Why?
| Disasters | 1 | 2017 | 19 | 0.030 |
Why?
| Inflammation | 1 | 2021 | 641 | 0.030 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2017 | 47 | 0.030 |
Why?
| Cricetulus | 1 | 2017 | 104 | 0.030 |
Why?
| Pyrazoles | 1 | 2018 | 114 | 0.030 |
Why?
| Cohort Studies | 1 | 2021 | 1542 | 0.030 |
Why?
| Gene Frequency | 1 | 2017 | 98 | 0.030 |
Why?
| CHO Cells | 1 | 2017 | 125 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2018 | 395 | 0.030 |
Why?
| Fires | 1 | 2016 | 15 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 240 | 0.030 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2016 | 9 | 0.030 |
Why?
| DNA Repair | 1 | 2018 | 195 | 0.030 |
Why?
| Taxoids | 1 | 2016 | 37 | 0.030 |
Why?
| Interleukin-1alpha | 1 | 2016 | 10 | 0.030 |
Why?
| Platelet-Derived Growth Factor | 1 | 2016 | 23 | 0.030 |
Why?
| Radiation Pneumonitis | 1 | 2016 | 11 | 0.030 |
Why?
| Poisson Distribution | 1 | 2016 | 36 | 0.030 |
Why?
| Receptors, Progesterone | 1 | 2016 | 66 | 0.030 |
Why?
| Hindlimb Suspension | 1 | 2016 | 37 | 0.030 |
Why?
| Diet | 1 | 2020 | 587 | 0.030 |
Why?
| Regression Analysis | 1 | 2017 | 401 | 0.030 |
Why?
| Particle Accelerators | 1 | 2016 | 51 | 0.030 |
Why?
| Dicumarol | 2 | 2005 | 3 | 0.030 |
Why?
| Cyclophosphamide | 1 | 2016 | 171 | 0.030 |
Why?
| Palinuridae | 1 | 2015 | 1 | 0.030 |
Why?
| Marine Biology | 1 | 2015 | 2 | 0.030 |
Why?
| Belize | 1 | 2015 | 2 | 0.030 |
Why?
| Receptors, Estrogen | 1 | 2016 | 131 | 0.030 |
Why?
| Carbonic Anhydrases | 1 | 2015 | 3 | 0.030 |
Why?
| Ecology | 1 | 2015 | 18 | 0.030 |
Why?
| Molecular Structure | 2 | 2008 | 314 | 0.030 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2015 | 56 | 0.030 |
Why?
| Recreation | 1 | 2015 | 21 | 0.030 |
Why?
| Muscular Atrophy | 1 | 2016 | 71 | 0.030 |
Why?
| Energy Metabolism | 1 | 2018 | 302 | 0.030 |
Why?
| Sulfur Dioxide | 1 | 2015 | 4 | 0.030 |
Why?
| Genotype | 1 | 2017 | 566 | 0.030 |
Why?
| Norepinephrine | 1 | 2015 | 112 | 0.030 |
Why?
| Models, Animal | 1 | 2016 | 234 | 0.030 |
Why?
| Epinephrine | 1 | 2015 | 97 | 0.030 |
Why?
| Mice, Knockout | 1 | 2017 | 879 | 0.030 |
Why?
| Risk | 1 | 2015 | 316 | 0.030 |
Why?
| Weight Gain | 1 | 2016 | 240 | 0.030 |
Why?
| Feeding Behavior | 1 | 2016 | 192 | 0.030 |
Why?
| Inhibitory Concentration 50 | 2 | 2004 | 74 | 0.030 |
Why?
| Culture Media | 2 | 2004 | 98 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 807 | 0.030 |
Why?
| Models, Immunological | 1 | 2013 | 8 | 0.030 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 33 | 0.030 |
Why?
| Protein Structure, Secondary | 1 | 2013 | 71 | 0.030 |
Why?
| Chronic Disease | 1 | 2015 | 586 | 0.030 |
Why?
| DNA Breaks, Double-Stranded | 1 | 2013 | 70 | 0.030 |
Why?
| Decision Making | 1 | 2015 | 282 | 0.020 |
Why?
| Light | 1 | 2013 | 73 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2016 | 1563 | 0.020 |
Why?
| Algorithms | 1 | 2016 | 672 | 0.020 |
Why?
| Mutation | 1 | 2018 | 1347 | 0.020 |
Why?
| Computer-Aided Design | 1 | 2011 | 20 | 0.020 |
Why?
| Equipment Failure Analysis | 1 | 2011 | 47 | 0.020 |
Why?
| Adjuvants, Pharmaceutic | 1 | 2011 | 4 | 0.020 |
Why?
| Phantoms, Imaging | 1 | 2011 | 122 | 0.020 |
Why?
| Equipment Design | 1 | 2011 | 293 | 0.020 |
Why?
| Volatilization | 1 | 2010 | 5 | 0.020 |
Why?
| Leukocyte Count | 1 | 2010 | 73 | 0.020 |
Why?
| Solvents | 1 | 2010 | 33 | 0.020 |
Why?
| Geography | 1 | 2010 | 65 | 0.020 |
Why?
| Glucagon-Like Peptide 1 | 1 | 2009 | 33 | 0.020 |
Why?
| Air | 1 | 2009 | 23 | 0.020 |
Why?
| Amides | 1 | 2009 | 37 | 0.020 |
Why?
| Dogs | 1 | 2009 | 180 | 0.020 |
Why?
| Retrospective Studies | 1 | 2022 | 6607 | 0.020 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 69 | 0.020 |
Why?
| Receptor, IGF Type 1 | 1 | 2009 | 22 | 0.020 |
Why?
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 28 | 0.020 |
Why?
| Thermal Conductivity | 1 | 2009 | 7 | 0.020 |
Why?
| Mammary Glands, Animal | 1 | 2009 | 69 | 0.020 |
Why?
| Binding, Competitive | 1 | 2009 | 90 | 0.020 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2010 | 339 | 0.020 |
Why?
| Pharmacokinetics | 1 | 2008 | 16 | 0.020 |
Why?
| Models, Statistical | 1 | 2010 | 230 | 0.020 |
Why?
| Child | 1 | 2021 | 7248 | 0.020 |
Why?
| Guinea Pigs | 1 | 2008 | 75 | 0.020 |
Why?
| Drug Design | 1 | 2009 | 120 | 0.020 |
Why?
| Isatin | 1 | 2008 | 1 | 0.020 |
Why?
| Bone Marrow | 1 | 2010 | 364 | 0.020 |
Why?
| Auditory Threshold | 1 | 2008 | 54 | 0.020 |
Why?
| Weight Loss | 1 | 2010 | 248 | 0.020 |
Why?
| Glycosylphosphatidylinositols | 1 | 2007 | 31 | 0.020 |
Why?
| Recurrence | 1 | 2009 | 672 | 0.020 |
Why?
| Rubidium | 1 | 2006 | 4 | 0.020 |
Why?
| Isoelectric Point | 1 | 2005 | 4 | 0.020 |
Why?
| Isoelectric Focusing | 1 | 2005 | 8 | 0.020 |
Why?
| Caffeine | 1 | 2006 | 61 | 0.020 |
Why?
| Peptide Mapping | 1 | 2005 | 22 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2009 | 1026 | 0.020 |
Why?
| Air Movements | 1 | 2005 | 1 | 0.020 |
Why?
| Liver | 1 | 2011 | 1156 | 0.010 |
Why?
| Cell Cycle | 1 | 2006 | 230 | 0.010 |
Why?
| Quality Control | 1 | 2005 | 96 | 0.010 |
Why?
| Tumor Stem Cell Assay | 1 | 2004 | 17 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2007 | 361 | 0.010 |
Why?
| Tennessee | 1 | 2003 | 37 | 0.010 |
Why?
| HL-60 Cells | 1 | 2003 | 19 | 0.010 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2009 | 560 | 0.010 |
Why?
| Solubility | 1 | 2003 | 79 | 0.010 |
Why?
| Cyclin B | 1 | 2003 | 4 | 0.010 |
Why?
| Cyclin B1 | 1 | 2003 | 7 | 0.010 |
Why?
| CDC2 Protein Kinase | 1 | 2003 | 16 | 0.010 |
Why?
| Water | 1 | 2003 | 82 | 0.010 |
Why?
| Heat-Shock Proteins | 1 | 2003 | 103 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2004 | 1546 | 0.010 |
Why?
|
|
Griffin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|